Vera Therapeutics Statistics
Total Valuation
VERA has a market cap or net worth of $1.43 billion. The enterprise value is $898.91 million.
Important Dates
The last earnings date was Tuesday, May 6, 2025, before market open.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VERA has 63.77 million shares outstanding. The number of shares has increased by 27.09% in one year.
| Current Share Class | 63.77M |
| Shares Outstanding | 63.77M |
| Shares Change (YoY) | +27.09% |
| Shares Change (QoQ) | +4.91% |
| Owned by Insiders (%) | 0.85% |
| Owned by Institutions (%) | 90.91% |
| Float | 50.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.68 |
| P/TBV Ratio | 2.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.68, with a Debt / Equity ratio of 0.10.
| Current Ratio | 27.68 |
| Quick Ratio | 27.10 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.73 |
Financial Efficiency
Return on equity (ROE) is -39.49% and return on invested capital (ROIC) is -24.25%.
| Return on Equity (ROE) | -39.49% |
| Return on Assets (ROA) | -23.46% |
| Return on Invested Capital (ROIC) | -24.25% |
| Return on Capital Employed (ROCE) | -32.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.57M |
| Employee Count | 112 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VERA has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.57% in the last 52 weeks. The beta is 1.28, so VERA's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -45.57% |
| 50-Day Moving Average | 24.57 |
| 200-Day Moving Average | 36.16 |
| Relative Strength Index (RSI) | 46.10 |
| Average Volume (20 Days) | 1,227,359 |
Short Selling Information
The latest short interest is 5.96 million, so 9.34% of the outstanding shares have been sold short.
| Short Interest | 5.96M |
| Short Previous Month | 6.08M |
| Short % of Shares Out | 9.34% |
| Short % of Float | 11.78% |
| Short Ratio (days to cover) | 5.64 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -193.25M |
| Pretax Income | -107.85M |
| Net Income | -175.46M |
| EBITDA | -193.07M |
| EBIT | -193.25M |
| Earnings Per Share (EPS) | -$3.00 |
Full Income StatementBalance Sheet
The company has $589.83 million in cash and $54.47 million in debt, giving a net cash position of $535.37 million or $8.39 per share.
| Cash & Cash Equivalents | 589.83M |
| Total Debt | 54.47M |
| Net Cash | 535.37M |
| Net Cash Per Share | $8.39 |
| Equity (Book Value) | 535.00M |
| Book Value Per Share | 8.39 |
| Working Capital | 584.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$155.26 million and capital expenditures -$1.16 million, giving a free cash flow of -$156.41 million.
| Operating Cash Flow | -155.26M |
| Capital Expenditures | -1.16M |
| Free Cash Flow | -156.41M |
| FCF Per Share | -$2.45 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |